Overview

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics and safety of multiple oral doses of ABT-450/ritonavir/ABT-267 and ABT-333 when co-administered under non-fasting conditions in healthy Chinese adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Ritonavir